ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Neuraxis Inc

Neuraxis Inc (NRXS)

2.54
0.00
( 0.00% )
Updated: 09:30:03

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.54
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
2.0001 52 Week Range 3.89
Market Cap
Previous Close
2.54
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
26,904
Shares Outstanding
6,980,227
Dividend Yield
-
PE Ratio
-1.21
Earnings Per Share (EPS)
-2.1
Revenue
2.46M
Net Profit
-14.63M

About Neuraxis Inc

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare ... NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana. Show more

Sector
Electromedical Apparatus
Industry
Electromedical Apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Neuraxis Inc is listed in the Electromedical Apparatus sector of the American Stock Exchange with ticker NRXS. The last closing price for Neuraxis was $2.54. Over the last year, Neuraxis shares have traded in a share price range of $ 2.0001 to $ 3.89.

Neuraxis currently has 6,980,227 shares outstanding. The market capitalization of Neuraxis is $17.73 million. Neuraxis has a price to earnings ratio (PE ratio) of -1.21.

NRXS Latest News

NeurAxis Inc. Issues Letter to Shareholders

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or...

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software. NeurAxis Inc. will...

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.11-4.150943396232.652.862.43204742.54757259CS
40.124.958677685952.423.342.25325662.4435512CS
12-0.26-9.285714285712.83.782.05269042.6955665CS
26-0.5-16.44736842113.043.782.05154462.76281395CS
520.166.722689075632.383.892.0001130232.87124313CS
156-3.76-59.68253968256.36.931.8201543.39018523CS
260-3.76-59.68253968256.36.931.8201543.39018523CS

NRXS - Frequently Asked Questions (FAQ)

What is the current Neuraxis share price?
The current share price of Neuraxis is $ 2.54
How many Neuraxis shares are in issue?
Neuraxis has 6,980,227 shares in issue
What is the market cap of Neuraxis?
The market capitalisation of Neuraxis is USD 17.73M
What is the 1 year trading range for Neuraxis share price?
Neuraxis has traded in the range of $ 2.0001 to $ 3.89 during the past year
What is the PE ratio of Neuraxis?
The price to earnings ratio of Neuraxis is -1.21
What is the cash to sales ratio of Neuraxis?
The cash to sales ratio of Neuraxis is 7.21
What is the reporting currency for Neuraxis?
Neuraxis reports financial results in USD
What is the latest annual turnover for Neuraxis?
The latest annual turnover of Neuraxis is USD 2.46M
What is the latest annual profit for Neuraxis?
The latest annual profit of Neuraxis is USD -14.63M
What is the registered address of Neuraxis?
The registered address for Neuraxis is 108 W. 13TH STREET SUITE 100, WILMINGTON, DELAWARE, 19801
What is the Neuraxis website address?
The website address for Neuraxis is www.neuraxis.com
Which industry sector does Neuraxis operate in?
Neuraxis operates in the ELECTROMEDICAL APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAPYKurv Yield Premium Strategy Apple AAPL ETF
$ 25.6901
(0.00%)
31
AAPXT Rex 2X Long Apple Daily Target ETF
$ 28.07
(0.00%)
1.57k
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
$ 26.3089
(0.00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
$ 26.32
(0.00%)
13.26k
AAAAlternative Access First Priority CLO Bond ETF
$ 25.21
(0.00%)
80
AAPYKurv Yield Premium Strategy Apple AAPL ETF
$ 25.6901
(0.00%)
31
AAPXT Rex 2X Long Apple Daily Target ETF
$ 28.07
(0.00%)
1.57k
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
$ 26.3089
(0.00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
$ 26.32
(0.00%)
13.26k
AAAAlternative Access First Priority CLO Bond ETF
$ 25.21
(0.00%)
80
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 27.85
(0.00%)
7.01M
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 9.23
(0.00%)
6.28M
KULRKULR Technology Group Inc
$ 2.21
(0.00%)
4.73M
CTMCastellum Inc
$ 0.7201
(0.00%)
4.49M
ETHU2x Ether ETF
$ 6.46
(0.00%)
4.11M

NRXS Discussion

View Posts
QuicKtip QuicKtip 1 year ago
$NRXS this is a massively strong buy right now.
👍️0
SidewaysTrader SidewaysTrader 1 year ago
Tested lowest support now let’s start back up
👍️0
budfoxfun budfoxfun 1 year ago
5.16 thin on the ask heading into the close!

$NRXS
👍️ 1
Golden Cross Golden Cross 1 year ago
NeurAxis Highlights Strength of its Board of Directors
https://finance.yahoo.com/news/neuraxis-highlights-strength-board-directors-130000862.html
👍️0
Golden Cross Golden Cross 1 year ago
$NRXS Closed strong at $6.01. Think we can see $7+ by the EOW... $14 price target here... $30B+ Total Addressable U.S. Market for Pipeline Indications.. Looking good!
👍️0
Golden Cross Golden Cross 1 year ago
$NRXS $30B+ Total Addressable U.S. Market for Pipeline Indications‼️

$9B+ Pediatric Addressable Market
$21B+ Adult Market

👍️0
Golden Cross Golden Cross 1 year ago
Bet we get nice continuation tomorrow $NRXS
👍️0
Golden Cross Golden Cross 1 year ago
NRXS In 13 Children's Hospital Sites. NRXS's focus is on the $9B pediatric market, for which no FDA cleared products exist and utilize the Company’s PENFS technology.
👍️0
Golden Cross Golden Cross 1 year ago
Looking for a move above $6 this week
👍️0
Golden Cross Golden Cross 1 year ago
Bid getting stronger here...
👍️0
budfoxfun budfoxfun 1 year ago
Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published independent studies showing that IB-Stim therapy leads to improvements in abdominal pain and disability in adolescents with IBS and that the gut microbiome may play an important role.

The publications, “The microbiome in adolescents with irritable bowel syndrome and changes with percutaneous electrical nerve field stimulation1,” authored by Daniel F. Castillo, et al, and “Impact of auricular percutaneous electrical nerve field stimulation on gut microbiome in adolescents with irritable bowel syndrome: a pilot study2,” authored by Geetanjalo Bora, et al, both highlight the effect of the gut microbiome in the treatment of adolescents with IBS using IB-Stim, NeurAxis’s proprietary technology.
👍️0
Golden Cross Golden Cross 1 year ago
$NRXS News Out➡️ NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome


#neuromodulation #FDA #Pediatric #FAP #IBS $MDT $CYBX $STJ $BSX $VIRI $JNJ $AMC

https://finance.yahoo.com/news/neuraxis-highlights-two-independent-studies-130000996.html
👍️0
Golden Cross Golden Cross 1 year ago
It wont take much volume to move this one
👍️0
Golden Cross Golden Cross 1 year ago
$14 price Target by Rob Goldman

👍️0
budfoxfun budfoxfun 1 year ago
$NRXS huge breakout coming soon, super thin on the ask! https://www.youtube.com/@ib-stim
👍️ 1
Golden Cross Golden Cross 1 year ago
Thanks, great technology here with $NRXS
👍️0
SpaceManTrades SpaceManTrades 1 year ago
$NRXS Check it out. Love the cutting-edge tech here. This is a small explainer video on how the Company is targeting a 9 Billion Dollar market. http://primetimeprofiles.com/web-stories/neuraxis/
👍️0
Golden Cross Golden Cross 1 year ago
$NRXS NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
https://ir.neuraxis.com/news-releases/news-release-details/neuraxis-announces-over-8-million-ib-stimtm-revenue

08/17/23
CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. NeurAxis is conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.

Approximately $2 million of the over $8 million in IB-Stim™ revenue through March 31, 2023 was generated in 2020 and 2019.

Brian Carrico, Chief Executive Officer of NeurAxis, said, “We are pleased to have reached over $8 million in sales of our proprietary IB-Stim™ technology and look forward building upon our momentum with the funds received from our recently completed IPO. We continue to drive increasing adoption of our IB-Stim™ therapy, supported by a significant and growing body of positive clinical data and commercial large health insurance company payor support. We believe the growing movement of patients gravitating towards non drug related therapies, especially for children, will continue to fuel our rapidly increasing adoption and the market for our new indications.”

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

The estimated revenues generated in 2019 and 2020 reflect our estimated financial results which were not audited nor reviewed by an independent registered public accounting firm.

Contacts:

Company
NeurAxis, Inc.
info @neuraxis.com

Investor Relations
Gilmartin Group
IR@neuraxis.com
👍️0
Golden Cross Golden Cross 1 year ago
NRXS Investor Presentation:
https://ir.neuraxis.com/news-events/presentations
👍️0
Golden Cross Golden Cross 1 year ago
COMPANY SNAPSHOT
NeurAxis, Inc., is a medical technology company
focused on neuromodulation therapies to address
chronic and debilitating conditions in children and
adults. NeurAxis is dedicated to advancing science
and leveraging evidence-based medicine to drive
adoption of its IB-Stim™ therapy, which is its
proprietary Percutaneous Electrical Nerve Field
Stimulation (PENFS) technology, by the medical,
scientific, and patient communities. IB-Stim™ is FDA
cleared for functional abdominal pain associated
with irritable bowel syndrome (IBS) in adolescents
11-18 years old. Additional clinical trials of PENFS
in multiple pediatric and adult conditions with large
unmet healthcare needs are underway.

$NRXS
👍️0

Your Recent History

Delayed Upgrade Clock